StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

Investment analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued on Friday. The firm set a “sell” rating on the stock.

Other equities research analysts have also issued reports about the stock. D. Boral Capital restated a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a report on Wednesday. Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Price Performance

NYSE:VNRX opened at $0.63 on Friday. The company has a market capitalization of $57.92 million, a price-to-earnings ratio of -1.74 and a beta of 1.20. The business has a 50 day moving average of $0.63 and a 200 day moving average of $0.66. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.23.

Insider Transactions at VolitionRx

In related news, CEO Cameron John Reynolds bought 139,811 shares of the company’s stock in a transaction on Monday, December 9th. The shares were acquired at an average cost of $0.57 per share, with a total value of $79,692.27. Following the completion of the acquisition, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at $1,206,920.28. The trade was a 7.07 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Guy Archibald Innes purchased 174,764 shares of the stock in a transaction dated Monday, December 9th. The stock was bought at an average cost of $0.57 per share, with a total value of $99,615.48. Following the transaction, the director now owns 617,085 shares in the company, valued at $351,738.45. The trade was a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 358,266 shares of company stock valued at $204,212 in the last three months. 12.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC boosted its holdings in VolitionRx Limited (NYSE:VNRX) by 15.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the quarter. Geode Capital Management LLC owned 0.79% of VolitionRx worth $439,000 at the end of the most recent quarter. Institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.